secwatch.observer — SEC 8-K summary
======================================

Issuer:     Praxis Precision Medicines, Inc. (PRAX)
CIK:        0001689548
Form:       8-K
Filed at:   2025-12-08T23:59:59+00:00
Accession:  0001689548-25-000114
Event type: other_material
Sentiment:  positive
Materiality: 0.85
Item codes: 8.01
LLM model:  deepseek-v4-flash:cloud@v2

Praxis gains FDA alignment for ulixacaltamide NDA; relutrigine & vormatrigine trials positive
--------------------------------------------------------------------------------

- Ulixacaltamide pre-NDA meeting with FDA completed; NDA submission expected early 2026.
- Relutrigine EMBOLD study stopped early for efficacy; 53% placebo-adjusted seizure reduction (p<0.0002) over 16 weeks.
- Relutrigine: 66% increase in motor seizure-free days (p=0.034); no drug-related serious adverse events.
- Vormatrigine RADIANT FOS cohort (n=62): 54% median seizure reduction at 8 weeks; 11% seizure-free for entire 8-week period.
- Vormatrigine POWER1 pivotal study fully enrolled; POWER2 on track for H2 2026; POWER3 monotherapy starts H1 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1689548/000168954825000114/0001689548-25-000114-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1689548/000168954825000114/prax-20251204.htm
  HTML page:      https://secwatch.observer/filing/0001689548-25-000114

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer